Skip to main content
Premium Trial:

Request an Annual Quote

QuantuMDx Raises $14M to Support Development of POC Genotyping Assay

NEW YORK – QuantuMDx said Monday that it has recently closed a $14 million financing round consisting of a mix of debt and ordinary equity.

The firm said it will use the funds, which were supported by existing shareholders, to support progress toward the commercial launch of its Q-POC high-risk HPV genotyping assay, planned for early 2021.

The Newcastle upon Tyne, UK-based company said that it has started the CE mark approval process of commissioned Q-POC devices and expects to certify them in the first half of this year.

"QuantuMDx’s Q-POC is the first true battery-operated, point-of-care molecular diagnostics device capable of performing both simple molecular tests and large syndromic and resistance mutation panels rapidly and at a price point appropriate for decentralized testing," Jonathan O’Halloran, cofounder and the new CEO of QuantuMDx, said in a statement.

The company is developing the device "to be robust for in-field testing and designed to manage dust, different ambient temperatures, humidity, and intermittent electricity," O'Halloran said.

In December, QuantuMDx and Santa Cruz, California-based Ontera announced that they are collaborating to develop technology for the detection of bloodstream infections and drug-resistance.

In November, QuantuMDx and SpeeDx announced a collaboration with the Foundation for Innovative New Diagnostics (FIND) to assess the feasibility of porting SpeeDx sexually transmitted infection tests to the QuantuMDx point-of-care testing device.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.